

Fycompa® (perampanel) – Expanded indication

- On September 28, 2018, <u>Eisai announced</u> the FDA approval of <u>Fycompa (perampanel)</u>, for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older.
 - Previously, Fycompa was approved for use in patients ≥ 12 years of age for this indication.
- Fycompa is also indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
- The approval of Fycompa for the treatment of POS in adolescents and children 4 to < 12 years is supported by evidence extrapolated from adequate and well-controlled studies of Fycompa in patients ≥ 12 years of age, pharmacokinetic data from adult and pediatric patients, and safety data in 225 pediatric patients 4 years to less than < 12 years of age.
- Fycompa carries a boxed warning for serious psychiatric and behavioral reactions.
- The recommended starting dose of Fycompa is 2 mg once daily taken orally at bedtime for both indications.
 - For POS, the recommended maintenance dose range is 8 mg to 12 mg once daily, although some patients may respond to a dose of 4 mg daily. A dose of 12 mg once daily resulted in somewhat greater reductions in seizure rates than the dose of 8 mg once daily, but with a substantial increase in adverse reactions.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.